tradingkey.logo

Dianthus Therapeutics Inc <DNTH.OQ> expected to post a loss of 85 cents a share - Earnings Preview

ReutersMay 5, 2025 11:46 AM
  • Dianthus Therapeutics Inc DNTH.OQ DNTH.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The New York City-based company is expected to report a 8.0% decrease in revenue to $804.3 thousand from $874 thousand a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Dianthus Therapeutics Inc is for a loss of 85 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $52.00​, above​ its last closing price of $21.70. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.88

-0.85

-0.81

Beat

4.8

Sep. 30 2024

-0.58

-0.59

-0.74

Missed

-24.5

Jun. 30 2024

-0.57

-0.55

-0.51

Beat

6.5​

Mar. 31 2024

-0.44

-0.44

-0.54

Missed

-23.3

​​Dec. 31 2023

-1.18

-1.01

-0.71

Beat

29.7

Sep. 30 2023

-0.56

-0.56

-3.78

Missed

-575​

Jun. 30 2023

-3.04

-3.04

-0.80

Beat

73.7

Mar. 31 2023

-6.56

-6.56

-7.68

Missed

-17.1

This summary was machine generated May 5 at 11:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI